Diabetic Macular EdemaPhase 4NCT05715385
Comparison of Treatments in Diabetic Macular Edema
A Phase 4 study testing laser photocoagulation and eye drop bromfenac 0.09% in people with Diabetic Macular Edema, run by Babasaheb Ambedkar Memorial Hospital.
Trial summary
Prospective or cohort study to compare the effects of grid macular laser, topical bromfenac 0.09% and placebo (carboxymethyl cellulose 0.5%) medication in diabetic macular edema. 60 eyes with macular edema of two types i.e. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Diabetic Macular Edema
- What is being tested?
- laser photocoagulation and eye drop bromfenac 0.09%
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- Nov 2014to Oct 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patient with type 1 or type 2 diabetes.
- The study eye met the following:
- OCT thickness of the macula upto 400 microns.
- On clinical examination, definite retinal thickening due to diabetic macular edema within 3000 μm of the center of the macula.
- Patient with well controlled blood sugar levels i.e. fasting blood sugar level < 110mg% and post prandial blood sugar level < 126 mg%. Also HbA1c level less than 7%.
- Able and willing to provide informed consent.
- Media clarity, pupillary dilation, and study participant cooperation sufficient for adequate OCT and fundus photographs.
- Normal optic disc.
Who cannot join
- Use of systemic corticosteroids for any other systemic condition or previous anti-Vascular endothelial growth factor (VEGF) therapy.
- Current use of prescription systemic NSAIDs.
- Known allergy to bromfenac.
- History of use of NSAID eye drops within the last 30 days or anticipated need for such drops during the study due to other ocular conditions.
- Any ocular condition, coexisting with diabetic macular edema, which might affect visual acuity.
About this study
Official title: Comparison Between Grid Macular Laser and Topical Bromfenac 0.09% in the Treatment of Diabetic Macular Edema
Prospective or cohort study to compare the effects of grid macular laser, topical bromfenac 0.09% and placebo (carboxymethyl cellulose 0.5%) medication in diabetic macular edema.
60 eyes with macular edema of two types i.e. cystoid macular edema (CME) and clinically significant macular edema (CSME) were divided into three groups with 20 patients in each group. One group was treated with grid laser photocoagulation, the second group was treated with topical bromfenac 0.09% drops two times a day and the third group was treated with topical carboxy methyl cellulose 0.5% three times a day (placebo treatment).
Read the detailed description
Study site:
Dr Babasaheb Ambedkar Memorial Hospital, of the Central Railway at Byculla, Mumbai.
Study Population:
Patients attending Ophthalmology Out Patient Department(OPD) at Dr Babasaheb Ambedkar Memorial Central Railway Hospital, Byculla, Mumbai.
Study design:
Prospective or cohort study to compare the effects of grid macular laser, topical bromfenac 0.09% and placebo (carboxymethyl cellulose 0.5%) medication in diabetic macular edema.
Sample size with justification:
60 eyes fulfilling the selection criteria were included in the study after informed consent.
Justification of sample size:
To calculate sample size formula used is N = Z2 * P (1-P) D2 Where, Z = standard normal deviate =1.96 (at 95% confidence interval) D = margin of error (precision) will be 0.05 P = Prevalence. According to Chennai Epidemiological Study99, the prevalence of diabetic retinopathy in India is 17.6%. Out of these, less than one third patients have mild macular edema.
So calculated sample size is 60 patients.
Time frame of the study:
Patients were randomly selected from those who were attending the OPD from November 2014 to October 2015.
Sampling procedure and data collection:
All the patients enrolled in the study were informed verbally about potential benefits and risks associated with the treatment modalities and a fully informed written consent was obtained from each of them.
A detailed history was obtained in each case. A thorough ophthalmic history regarding mode of onset of symptoms, duration of symptoms, a history of any previous intervention in the affected eye, medical history including duration of diabetes mellitus, medications being taken, and history of any other systemic illness was obtained and recorded on case record sheet. A comprehensive ophthalmic examination of all patients was done.
The patients were then divided by simple random sampling into three groups. One group was treated with grid laser photocoagulation, the second group was treated with topical bromfenac 0.09% drops two times a day and the third group was treated with topical carboxy methyl cellulose 0.5% three times a day (placebo treatment).
HISTORY AND EXAMINATION INCLUDED:
- General information: Name, age and sex ii. Chief complaints: The complaints patient presented with along with its onset, duration and progress. iii. Ophthalmic history:
- History of any ocular disease or injury which may affect vision and treatment taken for it.
- History of undergoing any ocular procedure. iv. History of diabetes mellitus especially with regard to its duration and treatment v. Visual acuity: Best corrected visual acuity (BCVA) testing was done on the ETDRS chart and values were obtained in logMAR for analysis. vi. Intraocular pressure measurement: Measured using Goldman applanation tonometer under topical anesthesia. vii. Slit lamp examination: For anterior segment examination to ensure clarity of lens and cornea. viii. Fundus examination: Fundus examination was done with slit lamp biomicroscopy using 60 dioptre lens and indirect ophthalmoscopy. Photographs were taken with fundus camera. ix. Optical coherence tomography (OCT) It was done at the beginning of the study before doing any intervention and then again after 6 weeks.
PROCEDURE:
- OCT machine used was Spectral Domain Cirrhus OCT from Carl Zeiss (Cirrhus High Definition-OCT)
- The pupils were dilated and the patient was positioned at the machine.
- A 512 * 128 macular cube protocol was chosen, consisting of 128 horizontal scan lines, each consisting of 512 A-scans per line. The instrument provided a retinal thickness map: 3 concentric circular areas were centered on the fixation point. The diameter of each was 1, 3 and 6 mm. In each one of these 9 areas, the software calculated the mean value from all the thickness measurements on each single A-scan. In addition to average retinal thickness of 9 zones, including a 1 mm central zone, the Cirrus macula readout provided macular volume and average macular thickness, which reflected the 3D structure of retina.
- The retinal thickness was measured from retinal pigment epithelium (RPE) to internal limiting membrane (ILM).
- Central macular thickness was calculated as mean thickness in the central 1000 um diameter area.
- Blood Investigations: Blood was checked for fasting blood sugar, post prandial blood sugar and HbA1c levels. The blood tests were repeated at the end of 6 weeks.
PROCEDURE OF GRID PHOTOCOAGULATION For the patients treated with laser photocoagulation, grid laser was performed under topical anesthesia with frequency doubled neodymium-doped yttrium aluminum garnet (Nd YAG) laser of wavelength 532 nm.
Laser Parameters for grid photocoagulation Lens used: Mainster grid lens Spot size: 75-100μ The burn intensity for grid laser: barely visible (light grey) Power: 80-100mw depending on the condition of the laser, the opacities in the media and background pigmentation.
Duration: 100msec No. of spots: 80-100 Laser burns were placed at least one burn width apart. Wider if the thickening was less severe. If necessary, the grid laser extended up to 2 disc diameters superiorly, inferiorly and temporally from the centre of the macula. Treating the area within 500 microns of the disc margin or the centre of the macula was avoided.
Patients in the bromfenac group were given twice daily e/d bromfenac 0.09% for 6 weeks.
Patients in the placebo group were given e/d carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
Follow up The patients were called every week and their visual acuity and fundus was checked.
The patients were instructed to maintain a good control diabetes, blood pressure and adhere to their follow up regimen and to report at the first sign of worsening vision.
The visual acuity, fundus photograph, macular thickness on OCT at 6 weeks checkup were used in present analysis.
Ethical consideration:
The investigator sought ethical clearance from Dr Babasaheb Ambedkar Memorial Central Railway Hospital, Byculla, Mumbai, ethical and scientific committee. Patients were included in this study only after they gave informed consent. Patients were informed of the purpose of the study, procedures to be performed and the risks and benefits of the treatment. As patients were on regular weekly follow up where vision and fundus was checked, even those patients receiving placebo had the benefit of a careful monitoring in place for intervention if required.
Data Management and Statistical Analysis:
- After data collection, data entry was done in excel.
- Statistical analysis was performed with the help of the software SPSS ver 15.
- For comparing quantitative data
- Between the study groups chi square test was applied
- Within the group that is before and after the study, paired 't' test was applied
- Comparison of non- parametric (qualitative) data between the study groups was done using Fisher Exact test
- Statistical significance is indicated by conventional symbols:
- p <0.05: Statistically significant
- p >0.05: Statistically non-significant
- Conditions
- Diabetic Macular Edema
- Being tested
- laser photocoagulation, eye drop bromfenac 0.09%, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
laser photocoagulationProcedure or surgery
Laser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion.
Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation.
Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula.
Duration of about 0.05-0.1 sec is used Number of spots- 100-500
eye drop bromfenac 0.09%Drug
twice daily e/d bromfenac 0.09% for 6 weeks
PlaceboDrug
Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Laser photocoagulation | Active comparator | Grid laser was performed under topical anesthesia with frequency doubled Nd YAG laser of wavelength 532 nm.
Laser Parameters for grid photocoagulation Lens used: Mainster grid lens Spot size: 75-100μ The burn intensity for grid laser: barely visible (light grey) Power: 80-100mw depending on the condition of the laser, the opacities in the media and background pigmentation.
Duration: 100msec No. of spots: 80-100 Laser burns were placed at least one burn width apart. Wider if the thickening was less severe. If necessary, the grid laser extended up to 2 disc diameters superiorly, inferiorly and temporally from the centre of the macula. Treating the area within 500 microns of the disc margin or the centre of the macula was avoided. Receives: Procedure: laser photocoagulation |
| Bromfenac 0.09% | Active comparator | Twice daily eye drop bromfenac 0.09% for 6 weeks Receives: Drug: eye drop bromfenac 0.09% |
| Observation | Placebo comparator | Eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in visual acuity in laser photocoagulation group
Best corrected visual acuity will be measured by logMAR scale
Measured: Baseline and 6 weeks
Change in visual acuity in bromfenac group
Best corrected visual acuity will be measured by logMAR scale
Measured: Baseline and 6 weeks
Change in visual acuity in observation group
Best corrected visual acuity will be measured by logMAR scale
Measured: Baseline and 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2023
- Study startNov 2014
- Primary completionOct 2015
- Study completionOct 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Diabetic Macular EdemaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Babasaheb Ambedkar Memorial Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Mehul Joshi, FRCS,DNB, Principal investigator, Dr Babasaheb Ambedkar Central Railway Hospital, Byculla, Mumbai, Maharashtra, IndiaArundhati Malviya, MS(Ophthal), Study chair, Dr Babasaheb Ambedkar Central Railway Hospital, Byculla, Mumbai, Maharashtra, IndiaMemuna Bahadur, MS(Ophthal), Study chair, Dr Babasaheb Ambedkar Central Railway Hospital, Byculla, Mumbai, Maharashtra, India
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05715385
- Sponsor's protocol ID
- 226-31122-142-201800
- Status last verified
- Feb 2023
- First submitted
- 13 Jan 2023
- Last updated
- 13 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The study protocol and findings will be made available as open source for all other researchers.
Publications
Pinna A, Blasetti F, Ricci GD, Boscia F. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol. 2017 May 11;27(3):326-330. doi: 10.5301/ejo.5000888. Epub 2016 Nov 16.
PubMed 28009414Busch C, Fraser-Bell S, Zur D, Rodriguez-Valdes PJ, Cebeci Z, Lupidi M, Fung AT, Gabrielle PH, Giancipoli E, Chaikitmongkol V, Okada M, Lains I, Santos AR, Kunavisarut P, Sala-Puigdollers A, Chhablani J, Ozimek M, Hilely A, Unterlauft JD, Loewenstein A, Iglicki M, Rehak M; International Retina Group. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetol. 2019 Jul;56(7):777-784. doi: 10.1007/s00592-019-01310-z. Epub 2019 Mar 22.
PubMed 30903434Baklayan GA, Munoz M. The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model. Clin Ophthalmol. 2014 Sep 4;8:1717-24. doi: 10.2147/OPTH.S66638. eCollection 2014.
PubMed 25228788Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013;2013:281981. doi: 10.1155/2013/281981. Epub 2013 Jan 14.
PubMed 23365785Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. doi: 10.1185/030079906X112471.
PubMed 16846546Ahmadi MA, Lim JI. Update on laser treatment of diabetic macular edema. Int Ophthalmol Clin. 2009 Spring;49(2):87-94. doi: 10.1097/IIO.0b013e31819fd6b2. No abstract available.
PubMed 19349789
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Grid Macular Laser and Topical Bromfenac 0.09% in the Treatment of Diabetic Macular Edema
- ClinicalTrials.gov ID
- NCT05715385
- Acronym / sponsor ID
- 226-31122-142-201800
- Conditions
- Diabetic Macular Edema
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Babasaheb Ambedkar Memorial HospitalOther government
- Study start
- Nov 2014 (actual)
- Primary completion
- Oct 2015 (actual)
- Study completion
- Oct 2015 (actual)
- First posted
- 8 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective or cohort study to compare the effects of grid macular laser, topical bromfenac 0.09% and placebo (carboxymethyl cellulose 0.5%) medication in diabetic macular edema.
60 eyes with macular edema of two types i.e. cystoid macular edema (CME) and clinically significant macular edema (CSME) were divided into three groups with 20 patients in each group. One group was treated with grid laser photocoagulation, the second group was treated with topical bromfenac 0.09% drops two times a day and the third group was treated with topical carboxy methyl cellulose 0.5% three times a day (placebo treatment).
Detailed description
Study site:
Dr Babasaheb Ambedkar Memorial Hospital, of the Central Railway at Byculla, Mumbai.
Study Population:
Patients attending Ophthalmology Out Patient Department(OPD) at Dr Babasaheb Ambedkar Memorial Central Railway Hospital, Byculla, Mumbai.
Study design:
Prospective or cohort study to compare the effects of grid macular laser, topical bromfenac 0.09% and placebo (carboxymethyl cellulose 0.5%) medication in diabetic macular edema.
Sample size with justification:
60 eyes fulfilling the selection criteria were included in the study after informed consent.
Justification of sample size:
To calculate sample size formula used is N = Z2 * P (1-P) D2 Where, Z = standard normal deviate =1.96 (at 95% confidence interval) D = margin of error (precision) will be 0.05 P = Prevalence. According to Chennai Epidemiological Study99, the prevalence of diabetic retinopathy in India is 17.6%. Out of these, less than one third patients have mild macular edema.
So calculated sample size is 60 patients.
Time frame of the study:
Patients were randomly selected from those who were attending the OPD from November 2014 to October 2015.
Sampling procedure and data collection:
All the patients enrolled in the study were informed verbally about potential benefits and risks associated with the treatment modalities and a fully informed written consent was obtained from each of them.
A detailed history was obtained in each case. A thorough ophthalmic history regarding mode of onset of symptoms, duration of symptoms, a history of any previous intervention in the affected eye, medical history including duration of diabetes mellitus, medications being taken, and history of any other systemic illness was obtained and recorded on case record sheet. A comprehensive ophthalmic examination of all patients was done.
The patients were then divided by simple random sampling into three groups. One group was treated with grid laser photocoagulation, the second group was treated with topical bromfenac 0.09% drops two times a day and the third group was treated with topical carboxy methyl cellulose 0.5% three times a day (placebo treatment).
HISTORY AND EXAMINATION INCLUDED:
- General information: Name, age and sex ii. Chief complaints: The complaints patient presented with along with its onset, duration and progress. iii. Ophthalmic history:
- History of any ocular disease or injury which may affect vision and treatment taken for it.
- History of undergoing any ocular procedure. iv. History of diabetes mellitus especially with regard to its duration and treatment v. Visual acuity: Best corrected visual acuity (BCVA) testing was done on the ETDRS chart and values were obtained in logMAR for analysis. vi. Intraocular pressure measurement: Measured using Goldman applanation tonometer under topical anesthesia. vii. Slit lamp examination: For anterior segment examination to ensure clarity of lens and cornea. viii. Fundus examination: Fundus examination was done with slit lamp biomicroscopy using 60 dioptre lens and indirect ophthalmoscopy. Photographs were taken with fundus camera. ix. Optical coherence tomography (OCT) It was done at the beginning of the study before doing any intervention and then again after 6 weeks.
PROCEDURE:
- OCT machine used was Spectral Domain Cirrhus OCT from Carl Zeiss (Cirrhus High Definition-OCT)
- The pupils were dilated and the patient was positioned at the machine.
- A 512 * 128 macular cube protocol was chosen, consisting of 128 horizontal scan lines, each consisting of 512 A-scans per line. The instrument provided a retinal thickness map: 3 concentric circular areas were centered on the fixation point. The diameter of each was 1, 3 and 6 mm. In each one of these 9 areas, the software calculated the mean value from all the thickness measurements on each single A-scan. In addition to average retinal thickness of 9 zones, including a 1 mm central zone, the Cirrus macula readout provided macular volume and average macular thickness, which reflected the 3D structure of retina.
- The retinal thickness was measured from retinal pigment epithelium (RPE) to internal limiting membrane (ILM).
- Central macular thickness was calculated as mean thickness in the central 1000 um diameter area.
- Blood Investigations: Blood was checked for fasting blood sugar, post prandial blood sugar and HbA1c levels. The blood tests were repeated at the end of 6 weeks.
PROCEDURE OF GRID PHOTOCOAGULATION For the patients treated with laser photocoagulation, grid laser was performed under topical anesthesia with frequency doubled neodymium-doped yttrium aluminum garnet (Nd YAG) laser of wavelength 532 nm.
Laser Parameters for grid photocoagulation Lens used: Mainster grid lens Spot size: 75-100μ The burn intensity for grid laser: barely visible (light grey) Power: 80-100mw depending on the condition of the laser, the opacities in the media and background pigmentation.
Duration: 100msec No. of spots: 80-100 Laser burns were placed at least one burn width apart. Wider if the thickening was less severe. If necessary, the grid laser extended up to 2 disc diameters superiorly, inferiorly and temporally from the centre of the macula. Treating the area within 500 microns of the disc margin or the centre of the macula was avoided.
Patients in the bromfenac group were given twice daily e/d bromfenac 0.09% for 6 weeks.
Patients in the placebo group were given e/d carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
Follow up The patients were called every week and their visual acuity and fundus was checked.
The patients were instructed to maintain a good control diabetes, blood pressure and adhere to their follow up regimen and to report at the first sign of worsening vision.
The visual acuity, fundus photograph, macular thickness on OCT at 6 weeks checkup were used in present analysis.
Ethical consideration:
The investigator sought ethical clearance from Dr Babasaheb Ambedkar Memorial Central Railway Hospital, Byculla, Mumbai, ethical and scientific committee. Patients were included in this study only after they gave informed consent. Patients were informed of the purpose of the study, procedures to be performed and the risks and benefits of the treatment. As patients were on regular weekly follow up where vision and fundus was checked, even those patients receiving placebo had the benefit of a careful monitoring in place for intervention if required.
Data Management and Statistical Analysis:
- After data collection, data entry was done in excel.
- Statistical analysis was performed with the help of the software SPSS ver 15.
- For comparing quantitative data
- Between the study groups chi square test was applied
- Within the group that is before and after the study, paired 't' test was applied
- Comparison of non- parametric (qualitative) data between the study groups was done using Fisher Exact test
- Statistical significance is indicated by conventional symbols:
- p <0.05: Statistically significant
- p >0.05: Statistically non-significant
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Laser photocoagulation | Active comparator | Procedure: laser photocoagulationGrid laser was performed under topical anesthesia with frequency doubled Nd YAG laser of wavelength 532 nm. Laser Parameters for grid photocoagulation Lens used: Mainster grid lens Spot size: 75-100μ The burn intensity for grid laser: barely visible (light grey) Power: 80-100mw depending on the condition of the laser, the opacities in the media and background pigmentation. Duration: 100msec No. of spots: 80-100 Laser burns were placed at least one burn width apart. Wider if the thickening was less severe. If necessary, the grid laser extended up to 2 disc diameters superiorly, inferiorly and temporally from the centre of the macula. Treating the area within 500 microns of the disc margin or the centre of the macula was avoided. |
| Bromfenac 0.09% | Active comparator | Drug: eye drop bromfenac 0.09%Twice daily eye drop bromfenac 0.09% for 6 weeks |
| Observation | Placebo comparator | Drug: PlaceboEye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- Patient with type 1 or type 2 diabetes.
- The study eye met the following:
- Patient with well controlled blood sugar levels i.e. fasting blood sugar level < 110mg% and post prandial blood sugar level < 126 mg%. Also HbA1c level less than 7%.
- Able and willing to provide informed consent.
- Media clarity, pupillary dilation, and study participant cooperation sufficient for adequate OCT and fundus photographs.
Key exclusion criteria (5 listed)
- Use of systemic corticosteroids for any other systemic condition or previous anti-Vascular endothelial growth factor (VEGF) therapy.
- Current use of prescription systemic NSAIDs.
- Known allergy to bromfenac.
- History of use of NSAID eye drops within the last 30 days or anticipated need for such drops during the study due to other ocular conditions.
- Any ocular condition, coexisting with diabetic macular edema, which might affect visual acuity.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| laser photocoagulationLaser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion. Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation. Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula. Duration of about 0.05-0.1 sec is used Number of spots- 100-500 | Procedure or surgery | Laser photocoagulation |
| eye drop bromfenac 0.09%twice daily e/d bromfenac 0.09% for 6 weeks | Drug | Bromfenac 0.09% |
| PlaceboObservation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks. | Drug | Observation |
Primary outcome
Change in visual acuity in laser photocoagulation group
Time frame: Baseline and 6 weeks
Best corrected visual acuity will be measured by logMAR scale
Change in visual acuity in bromfenac group
Time frame: Baseline and 6 weeks
Best corrected visual acuity will be measured by logMAR scale
Change in visual acuity in observation group
Time frame: Baseline and 6 weeks
Best corrected visual acuity will be measured by logMAR scale
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2023.
- Background: PubMed 28009414Pinna A, Blasetti F, Ricci GD, Boscia F. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol. 2017 May 11;27(3):326-330. doi: 10.5301/ejo.5000888. Epub 2016 Nov 16.
- Background: PubMed 30903434Busch C, Fraser-Bell S, Zur D, Rodriguez-Valdes PJ, Cebeci Z, Lupidi M, Fung AT, Gabrielle PH, Giancipoli E, Chaikitmongkol V, Okada M, Lains I, Santos AR, Kunavisarut P, Sala-Puigdollers A, Chhablani J, Ozimek M, Hilely A, Unterlauft JD, Loewenstein A, Iglicki M, Rehak M; International Retina Group. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetol. 2019 Jul;56(7):777-784. doi: 10.1007/s00592-019-01310-z. Epub 2019 Mar 22.
- Background: PubMed 25228788Baklayan GA, Munoz M. The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model. Clin Ophthalmol. 2014 Sep 4;8:1717-24. doi: 10.2147/OPTH.S66638. eCollection 2014.
- Background: PubMed 23365785Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013;2013:281981. doi: 10.1155/2013/281981. Epub 2013 Jan 14.
- Background: PubMed 16846546Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. doi: 10.1185/030079906X112471.
- Background: PubMed 19349789Ahmadi MA, Lim JI. Update on laser treatment of diabetic macular edema. Int Ophthalmol Clin. 2009 Spring;49(2):87-94. doi: 10.1097/IIO.0b013e31819fd6b2. No abstract available.
- Individual participant dataSharing planned: Yes. The study protocol and findings will be made available as open source for all other researchers.
Related trials for Diabetic Macular Edema
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 2
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
Diabetic Retinopathy, DR
RecruitingPhase 3
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
Diabetic Macular Edema (DME)
RecruitingPhase 2
Oral N-Acetylcysteine on Diabetic Macular Edema
Diabetic Macular Edema (DME)
Active, not recruitingPhase 3
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Diabetic Macular Edema, DME
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mehul Joshi, FRCS,DNB principal investigator
Dr Babasaheb Ambedkar Central Railway Hospital, Byculla, Mumbai, Maharashtra, India
Arundhati Malviya, MS(Ophthal) study chair
Dr Babasaheb Ambedkar Central Railway Hospital, Byculla, Mumbai, Maharashtra, India
Memuna Bahadur, MS(Ophthal) study chair
Dr Babasaheb Ambedkar Central Railway Hospital, Byculla, Mumbai, Maharashtra, India
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing laser photocoagulation and eye drop bromfenac 0.09% in people with Diabetic Macular Edema, run by Babasaheb Ambedkar Memorial Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in visual acuity in laser photocoagulation group (time frame: Baseline and 6 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05715385, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2023.